AI Bioinformatics platforms apply artificial intelligence to biological and genomic data analysis. These tools help researchers understand biological systems, discover new drugs, and advance medical research through sophisticated data processing and analysis capabilities.
46 verified AI-first sites in Bioinformatics.
Last reviewed .
Open-source Python library for deep learning in drug discovery, chemistry, materials science, and biology. Molecular featurizers, graph neural networks, property prediction, and model zoos with tutorials for researchers building scientific ML.
Pricing: Open source. Enterprise support: Contact for pricing.
Generative AI drug discovery company with its own clinical pipeline. Pharma.AI suite spans PandaOmics target discovery, Chemistry42 molecule design, Generative Biologics, inClinico trial prediction, and the Nach01 science model; its AI-discovered drugs include programs in fibrosis and oncology.
Pricing: Enterprise pricing. Contact for solutions.
AI drug discovery company combining phenomics, automated wet labs, and one of biotech's largest supercomputers. The Recursion OS maps biology from billions of cellular images and chemistry data (expanded by its Exscientia merger) to drive a clinical oncology and rare-disease pipeline and partnerships with Genentech and Sanofi.
Pricing: Enterprise solutions. Contact for pricing.
EMBL-EBI AlphaFold Protein Structure Database with hundreds of millions of AI-predicted 3D structures. Sequence search, downloadable models, and confidence metrics used across structural biology and drug discovery research.
Pricing: Free for research use. See EMBL-EBI terms for bulk and commercial access.
Causal AI drug discovery company founded by Daphne Koller. Combines 20+ petabytes of automated cellular experiments with population-scale genetics in its Virtual Human engine to find causal disease targets and develop therapeutics in neuroscience and metabolism.
Pricing: Enterprise partnerships and collaborations.
AI small-molecule discovery platform (Atomwise team/technology). Machine learning for structure-based screening and chemical-space exploration aimed at first- and best-in-class candidates for immune and inflammatory disease.
Pricing: Partnership-based pricing for enterprises.
Life science intelligence company, now private after its 2025 delisting. Qor, built on BenevolentAI's biomedical knowledge graph and ontologies, gives biopharma leaders and consultancies always-on competitive monitoring, scenario testing, and explainable strategy briefings; a smaller AI-derived pipeline (BEN-8744 in ulcerative colitis) is partnered early.
Pricing: Qor subscriptions for biopharma teams; book a demo.
AI cell morphology platform (REM-I) that images, analyzes, and sorts viable cells label-free using deep learning and a Human Foundation Model. Used for cell biology, cancer, and cell therapy research; collaborating with Gilead on a custom CHO cell morphology foundation model.
Pricing: Enterprise: Custom pricing based on usage requirements.
Platform for DNA and RNA bio foundation models focused on drug discovery. Features target identification, biomarker discovery, mRNA sequence design, and patient stratification capabilities. Provides data atlas and AI infrastructure for model training.
Pricing: Contact for pricing
Protein design platform using machine learning for protein engineering and optimization. Features AI-driven protein sequence design, property prediction, and optimization. Includes automated protein engineering workflows with AI-powered design suggestions. Offers comprehensive protein design tools with machine learning integration. Features integration with experimental data and laboratory workflows. Includes AI-driven insights for protein engineering and development. Provides advanced protein design capabilities with AI assistance. Particularly valuable for biotechnology companies and research institutions seeking AI-powered protein engineering and design solutions.
Pricing: Contact for pricing. Enterprise licensing available.
Generative AI and robotics for small-molecule drug discovery: de novo design, synthesis planning, and lab automation to shorten lead optimization cycles.
Pricing: Enterprise platform licensing for pharma and biotech.
Molecular AI platform for structure-based drug discovery with generative 3D models aimed at difficult protein targets and hit-to-lead acceleration.
Pricing: Enterprise partnerships and platform access.
AI drug discovery company building next-generation computational biology and drug design systems beyond structure prediction. Focuses on modeling protein-ligand interactions, design optimization, and accelerating small-molecule and biologics discovery workflows.
Pricing: Enterprise partnerships and collaboration-based engagements.
AI-driven drug discovery platform combining machine learning, physics-based simulation, and automation to support hit discovery, lead optimization, and preclinical research. Includes integrated software and lab automation capabilities for pharma R&D workflows.
Pricing: Enterprise and partnership pricing; see site for current options.
Generative AI platform for biologics discovery and therapeutic antibody design. Uses integrated AI models and experimental data loops to optimize candidate molecules across affinity, developability, and safety-related constraints.
Pricing: Partnership and enterprise pricing; contact for details.
AI-native therapeutics company applying machine learning to RNA biology and genetic medicine. Features models that link sequence and splicing to design oligonucleotide candidates and prioritize targets. Includes discovery through development programs across neuromuscular and related indications. Supports programmable therapeutic design with large-scale genomic and transcriptomic training data.
Pricing: Public company; see site for pipeline and investor materials.
Foundation-model company for biomedical AI spanning imaging, omics, and clinical-scale data. Features histopathology models (H-Optimus family) and multimodal biology embeddings (M-Optimus) for research and translational workflows. Includes APIs and enterprise access for digital pathology, biomarker discovery, and drug R&D teams. Particularly valuable for groups standardizing on shared biological representations across siloed datasets.
Pricing: Enterprise and research programs; contact via site for access and pricing.
AI-native protein engineering company using generative models and high-throughput lab cycles to design novel therapeutic proteins. Targets immune-mediated diseases with machine-learning-guided design and rapid experimental validation.
Pricing: Biotech platform and partnership model; contact for collaboration details.
Generative biology platform combining machine learning and biological engineering to create novel therapeutic proteins. Uses a closed-loop compute-and-experiment system to accelerate medicine design across multiple therapeutic modalities.
Pricing: Drug discovery platform and partnership model; contact for enterprise and pipeline collaboration.
Public-benefit biomolecular AI lab with open Boltz-1, Boltz-2, and BoltzGen models for structure prediction, binding affinity, and generative design. Boltz Lab platform provides production agents for small-molecule and protein workflows with API and CLI access. Used by 100K+ scientists; Pfizer partnership for custom foundation models.
Pricing: Free credits on Boltz Lab; API and enterprise plans; see site.
Frontier AI for predicting and reprogramming biochemical molecular interactions. Chai-1 open multimodal structure model; Chai-2 enables de novo antibody and miniprotein design with strong wet-lab validation rates. Lab server and open model weights for academic and commercial drug discovery.
Pricing: Lab access and commercial licensing; contact for enterprise.
AI-first protein design company building foundation models for functional protein engineering. Features ProGen and Profluent-E1 models for sequence design, fitness prediction, and wet-lab validation loops across enzymes, binders, and genome-editing tools.
Pricing: Research and enterprise programs; contact via site for access.
Open-source protein structure prediction stack and community benchmark for AlphaFold-class models. Provides trainable OpenFold code, weights, and reproducible pipelines for academic and commercial structural biology teams.
Pricing: Open source (Apache 2.0).
Open biomolecular structure prediction model from ByteDance AML reaching AlphaFold3-class accuracy on protein, nucleic acid, and ligand complexes. Offers open weights, training code, and an online structure prediction service.
Pricing: Free open-weights release; hosted inference on site.
Google DeepMind web service for AlphaFold 3 biomolecular structure prediction. Models proteins with DNA, RNA, ligands, ions, and chemical modifications for non-commercial research. Free browser access without local GPU setup for academic and nonprofit scientists.
Pricing: Free for non-commercial research; see AlphaFold Server terms.
Meta AI open atlas of hundreds of millions of metagenomic protein structures predicted with ESMFold. Searchable structure database for exploring the dark proteome and evolutionary protein space at scale.
Pricing: Free open access for research; see Meta ESM Atlas terms.
Frontier generative biology lab (AlphaFold alumni) building models for all molecules of life. Latent-X/X2 for de novo protein binders and antibodies; Latent-Y agent designs lab-ready sequences from natural-language therapeutic goals.
Pricing: Research tier with free daily designs; enterprise partnerships; see latentlabs.com.
Foundation models of life for sequence-based medicines (mRNA, siRNA, ASOs, peptides). End-to-end models trained on sequence, structure, and function with in-house wet-lab validation; Alnylam collaboration on RNAi therapeutics.
Pricing: Partnership and enterprise programs; see inceptive.com.
Biohub platform for the ESM protein model family, home of the EvolutionaryScale team since it joined Biohub. ESMC protein language model, ESMFold2 complex structure prediction and design, ESM3, and an open ESM Atlas of 6.8 billion annotated proteins and 1.1 billion predicted structures, with API and developer console access.
Pricing: Open models and researcher access via forge.biohub.ai; see Biohub terms.
Google DeepMind AI model for interpreting genome sequences and predicting regulatory effects. Maps DNA variants to molecular and cellular outcomes to accelerate genomics research and genetic medicine discovery.
Pricing: Research access via Google DeepMind-see AlphaGenome.
AI protein design platform for antibodies and biologics. Generates and optimizes binder sequences with ML so drug discovery teams explore protein space faster than traditional library screening alone.
Pricing: Partnership and platform plans-see Nabla.
AI-driven genetic medicines and genome engineering platform. Supports AAV, gene therapy, and editing workflows with computational design and analytics for biotech teams building genetic therapies.
Pricing: Contact Form Bio for pricing.
Frontier AI for precision oncology from multimodal biological data. Builds models over spatial and molecular tumor profiles to guide discovery and patient stratification decisions.
Pricing: Partnerships-see Noetik.
AI drug discovery company linking genetics, single-cell biology, and machine learning. Discovers targets and programs from human disease biology with an integrated computational and experimental stack.
Pricing: Pipeline and partnerships-see Relation.
Physics-based generative AI for peptide drug design. MAUD 1.0 designs peptide macrocycles de novo for hard targets such as protein-protein interfaces, with reported nM potency, oral bioavailability, and cell permeability for top-10 pharma partners.
Pricing: Contact Menten AI for partnerships.
AI protein design company for industrial enzymes and biosolutions. Engineers proteins for chemicals, materials, and food applications using computational design plus lab validation.
Pricing: Enterprise partnerships-see Arzeda.
AI enzyme design for biomanufacturing. Designs novel enzymes for chemical production pathways so industry can replace harsh processes with programmable biology.
Pricing: Contact Enzymit for pricing.
Frontier AI for therapeutic design trained on biodiversity data from all seven continents: 100 billion+ novel genes and 100T+ tokens. The 28B-parameter EDEN model powers a gene insertion, gene editing, and peptide therapeutic pipeline, backed by $140M in new funding; some EDEN capabilities are available through Claude.
Pricing: Partnerships-see Basecamp Research.
AI drug discovery platform tightly coupled to ultra-large experimental chemistry. Iterates designs with wet-lab feedback for small-molecule programs at industrial scale.
Pricing: Pipeline partnerships-see Terray.
AI design of AAV gene therapy delivery vectors. Machine learning optimizes capsids for tissue targeting and manufacturability to power genetic medicines with better tropism.
Pricing: Partnerships-see Dyno.
AI platform for peptide therapeutics and delivery. Designs peptide-based drugs with computational methods aimed at harder-to-drug targets and improved biodistribution.
Pricing: Contact ProteinQure for partnerships.
AI agents and benchmarks for biology R&D. Evaluates research agents on experimentally grounded tasks across discovery, genomics, and biosecurity-plus cloud workflows for computational biology teams.
Pricing: Free tier and paid plans-see LatchBio.
CZ Biohub AI-supported virtual cell models platform. Shared models and tools for simulating cellular biology to accelerate open scientific discovery across labs.
Pricing: Open research platform-see CZ Biohub.
NVIDIA BioNeMo framework for building and adapting AI models for drug discovery and molecular biology. Tooling for biomolecular generative models and large-scale training.
Pricing: Open framework docs; NVIDIA cloud and enterprise options-see BioNeMo.
AI drug discovery company launched with more than $1B in funding and led by former Genentech CSO Marc Tessier-Lavigne, with David Baker lab protein design alumni. Generates biological data at scale (X-Atlas/Pisces, X-Cell) and trains models on it to design antibodies and other therapeutics; won the 2026 Fierce AI Innovation Award for preclinical development.
Pricing: Partnerships and collaborations; contact Xaira.
AI drug discovery company building a molecular superintelligence platform. The Enchant multimodal transformer and NeuralPLexer co-folding models drive a high-throughput experimental loop that turns new molecular designs into biological data each week, feeding an internal clinical oncology pipeline and partner programs.
Pricing: Partnerships; contact Iambic.